Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of
dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic suspension
is more effective than vehicle in treating signs of dry eye disease.